GEO Accession viewer

GSM3020220	ATAC-seq on PBMCs from donor ND-1, CD4Tcell
GSM3020221	ATAC-seq on PBMCs from donor ND-2, CD4Tcell
GSM3020222	ATAC-seq on PBMCs from donor ND-3, CD4Tcell
GSM3020223	ATAC-seq on PBMCs from donor ND-1, CD8Tcell
GSM3020224	ATAC-seq on PBMCs from donor ND-2, CD8Tcell
GSM3020225	ATAC-seq on PBMCs from donor ND-3, CD8Tcell
GSM3020226	ATAC-seq on PBMCs from donor ND-1, NaiveBcell
GSM3020227	ATAC-seq on PBMCs from donor ND-2, NaiveBcell
GSM3020228	ATAC-seq on PBMCs from donor ND-3, NaiveBcell
GSM3020229	ATAC-seq on PBMCs from donor ND-1, SwitchedBcell
GSM3020230	ATAC-seq on PBMCs from donor ND-2, SwitchedBcell
GSM3020231	ATAC-seq on PBMCs from donor ND-3, SwitchedBcell
GSM3020232	ATAC-seq on PBMCs from donor ND-1, Tcell
GSM3020233	ATAC-seq on PBMCs from donor ND-2, Tcell
GSM3020234	ATAC-seq on PBMCs from donor ND-3, Tcell
GSM3020235	ATAC-seq on PBMCs from donor ND-1, UnswitchedBcell
GSM3020236	ATAC-seq on PBMCs from donor ND-2, UnswitchedBcell
GSM3020237	ATAC-seq on PBMCs from donor ND-3, UnswitchedBcell
GSM3020238	ATAC-seq on PBMCs from patient CLL1 on day 0 of ibrutinib treatment, Bcell cells
GSM3020239	ATAC-seq on PBMCs from patient CLL1 on day 3 of ibrutinib treatment, Bcell cells
GSM3020240	ATAC-seq on PBMCs from patient CLL1 on day 120 of ibrutinib treatment, Bcell cells
GSM3020241	ATAC-seq on PBMCs from patient CLL1 on day 0 of ibrutinib treatment, CD4 cells
GSM3020242	ATAC-seq on PBMCs from patient CLL1 on day 3 of ibrutinib treatment, CD4 cells
GSM3020243	ATAC-seq on PBMCs from patient CLL1 on day 120 of ibrutinib treatment, CD4 cells, replicate 1
GSM3020244	ATAC-seq on PBMCs from patient CLL1 on day 120 of ibrutinib treatment, CD4 cells, replicate 2
GSM3020245	ATAC-seq on PBMCs from patient CLL1 on day 0 of ibrutinib treatment, CD8 cells
GSM3020246	ATAC-seq on PBMCs from patient CLL1 on day 3 of ibrutinib treatment, CD8 cells
GSM3020247	ATAC-seq on PBMCs from patient CLL1 on day 030 of ibrutinib treatment, CD8 cells
GSM3020248	ATAC-seq on PBMCs from patient CLL1 on day 120 of ibrutinib treatment, CD8 cells
GSM3020249	ATAC-seq on PBMCs from patient CLL1 on day 0 of ibrutinib treatment, CLL cells
GSM3020250	ATAC-seq on PBMCs from patient CLL1 on day 3 of ibrutinib treatment, CLL cells
GSM3020251	ATAC-seq on PBMCs from patient CLL1 on day 030 of ibrutinib treatment, CLL cells
GSM3020252	ATAC-seq on PBMCs from patient CLL1 on day 120 of ibrutinib treatment, CLL cells
GSM3020253	ATAC-seq on PBMCs from patient CLL1 on day 0 of ibrutinib treatment, NK cells
GSM3020254	ATAC-seq on PBMCs from patient CLL1 on day 3 of ibrutinib treatment, NK cells
GSM3020255	ATAC-seq on PBMCs from patient CLL1 on day 120 of ibrutinib treatment, NK cells, replicate 1
GSM3020256	ATAC-seq on PBMCs from patient CLL1 on day 120 of ibrutinib treatment, NK cells, replicate 2
GSM3020257	ATAC-seq on PBMCs from patient CLL2 on day 0 of ibrutinib treatment, Bcell cells
GSM3020258	ATAC-seq on PBMCs from patient CLL2 on day 3 of ibrutinib treatment, Bcell cells
GSM3020259	ATAC-seq on PBMCs from patient CLL2 on day 30 of ibrutinib treatment, Bcell cells
GSM3020260	ATAC-seq on PBMCs from patient CLL2 on day 120 of ibrutinib treatment, Bcell cells
GSM3020261	ATAC-seq on PBMCs from patient CLL2 on day 0 of ibrutinib treatment, CD4 cells
GSM3020262	ATAC-seq on PBMCs from patient CLL2 on day 3 of ibrutinib treatment, CD4 cells
GSM3020263	ATAC-seq on PBMCs from patient CLL2 on day 8 of ibrutinib treatment, CD4 cells
GSM3020264	ATAC-seq on PBMCs from patient CLL2 on day 30 of ibrutinib treatment, CD4 cells
GSM3020265	ATAC-seq on PBMCs from patient CLL2 on day 120 of ibrutinib treatment, CD4 cells
GSM3020266	ATAC-seq on PBMCs from patient CLL2 on day 0 of ibrutinib treatment, CD8 cells
GSM3020267	ATAC-seq on PBMCs from patient CLL2 on day 3 of ibrutinib treatment, CD8 cells
GSM3020268	ATAC-seq on PBMCs from patient CLL2 on day 8 of ibrutinib treatment, CD8 cells
GSM3020269	ATAC-seq on PBMCs from patient CLL2 on day 30 of ibrutinib treatment, CD8 cells
GSM3020270	ATAC-seq on PBMCs from patient CLL2 on day 120 of ibrutinib treatment, CD8 cells
GSM3020271	ATAC-seq on PBMCs from patient CLL2 on day 0 of ibrutinib treatment, CLL cells
GSM3020272	ATAC-seq on PBMCs from patient CLL2 on day 3 of ibrutinib treatment, CLL cells
GSM3020273	ATAC-seq on PBMCs from patient CLL2 on day 8 of ibrutinib treatment, CLL cells
GSM3020274	ATAC-seq on PBMCs from patient CLL2 on day 30 of ibrutinib treatment, CLL cells
GSM3020275	ATAC-seq on PBMCs from patient CLL2 on day 120 of ibrutinib treatment, CLL cells
GSM3020276	ATAC-seq on PBMCs from patient CLL2 on day 3 of ibrutinib treatment, Mono cells
GSM3020277	ATAC-seq on PBMCs from patient CLL2 on day 120 of ibrutinib treatment, Mono cells
GSM3020278	ATAC-seq on PBMCs from patient CLL2 on day 3 of ibrutinib treatment, NK cells
GSM3020279	ATAC-seq on PBMCs from patient CLL2 on day 8 of ibrutinib treatment, NK cells
GSM3020280	ATAC-seq on PBMCs from patient CLL2 on day 30 of ibrutinib treatment, NK cells
GSM3020281	ATAC-seq on PBMCs from patient CLL2 on day 150 of ibrutinib treatment, NK cells
GSM3020282	ATAC-seq on PBMCs from patient CLL4 on day 3 of ibrutinib treatment, Bcell cells
GSM3020283	ATAC-seq on PBMCs from patient CLL4 on day 0 of ibrutinib treatment, CD4 cells
GSM3020284	ATAC-seq on PBMCs from patient CLL4 on day 2 of ibrutinib treatment, CD4 cells
GSM3020285	ATAC-seq on PBMCs from patient CLL4 on day 3 of ibrutinib treatment, CD4 cells
GSM3020286	ATAC-seq on PBMCs from patient CLL4 on day 0 of ibrutinib treatment, CD8 cells
GSM3020287	ATAC-seq on PBMCs from patient CLL4 on day 3 of ibrutinib treatment, CD8 cells
GSM3020288	ATAC-seq on PBMCs from patient CLL4 on day 0 of ibrutinib treatment, CLL cells
GSM3020289	ATAC-seq on PBMCs from patient CLL4 on day 2 of ibrutinib treatment, CLL cells
GSM3020290	ATAC-seq on PBMCs from patient CLL4 on day 3 of ibrutinib treatment, CLL cells
GSM3020291	ATAC-seq on PBMCs from patient CLL4 on day 0 of ibrutinib treatment, Mono cells
GSM3020292	ATAC-seq on PBMCs from patient CLL4 on day 3 of ibrutinib treatment, Mono cells
GSM3020293	ATAC-seq on PBMCs from patient CLL4 on day 0 of ibrutinib treatment, NK cells
GSM3020294	ATAC-seq on PBMCs from patient CLL4 on day 3 of ibrutinib treatment, NK cells
GSM3020295	ATAC-seq on PBMCs from patient CLL5 on day 0 of ibrutinib treatment, Bcells, replicate 1
GSM3020296	ATAC-seq on PBMCs from patient CLL5 on day 0 of ibrutinib treatment, Bcells, replicate 2
GSM3020297	ATAC-seq on PBMCs from patient CLL5 on day 1 of ibrutinib treatment, Bcell cells
GSM3020298	ATAC-seq on PBMCs from patient CLL5 on day 2 of ibrutinib treatment, Bcell cells
GSM3020299	ATAC-seq on PBMCs from patient CLL5 on day 3 of ibrutinib treatment, Bcell cells
GSM3020300	ATAC-seq on PBMCs from patient CLL5 on day 8 of ibrutinib treatment, Bcell cells
GSM3020301	ATAC-seq on PBMCs from patient CLL5 on day 30 of ibrutinib treatment, Bcell cells
GSM3020302	ATAC-seq on PBMCs from patient CLL5 on day 150 of ibrutinib treatment, Bcell cells
GSM3020303	ATAC-seq on PBMCs from patient CLL5 on day 0 of ibrutinib treatment, CD4 cells
GSM3020304	ATAC-seq on PBMCs from patient CLL5 on day 1 of ibrutinib treatment, CD4 cells
GSM3020305	ATAC-seq on PBMCs from patient CLL5 on day 2 of ibrutinib treatment, CD4 cells
GSM3020306	ATAC-seq on PBMCs from patient CLL5 on day 3 of ibrutinib treatment, CD4 cells
GSM3020307	ATAC-seq on PBMCs from patient CLL5 on day 8 of ibrutinib treatment, CD4 cells
GSM3020308	ATAC-seq on PBMCs from patient CLL5 on day 30 of ibrutinib treatment, CD4 cells
GSM3020309	ATAC-seq on PBMCs from patient CLL5 on day 150 of ibrutinib treatment, CD4 cells
GSM3020310	ATAC-seq on PBMCs from patient CLL5 on day 240 of ibrutinib treatment, CD4 cells
GSM3020311	ATAC-seq on PBMCs from patient CLL5 on day 0 of ibrutinib treatment, CD8 cells
GSM3020312	ATAC-seq on PBMCs from patient CLL5 on day 1 of ibrutinib treatment, CD8 cells
GSM3020313	ATAC-seq on PBMCs from patient CLL5 on day 2 of ibrutinib treatment, CD8 cells
GSM3020314	ATAC-seq on PBMCs from patient CLL5 on day 3 of ibrutinib treatment, CD8 cells
GSM3020315	ATAC-seq on PBMCs from patient CLL5 on day 8 of ibrutinib treatment, CD8 cells
GSM3020316	ATAC-seq on PBMCs from patient CLL5 on day 30 of ibrutinib treatment, CD8 cells
GSM3020317	ATAC-seq on PBMCs from patient CLL5 on day 150 of ibrutinib treatment, CD8 cells
GSM3020318	ATAC-seq on PBMCs from patient CLL5 on day 240 of ibrutinib treatment, CD8 cells
GSM3020319	ATAC-seq on PBMCs from patient CLL5 on day 0 of ibrutinib treatment, CLL cells
GSM3020320	ATAC-seq on PBMCs from patient CLL5 on day 1 of ibrutinib treatment, CLL cells
GSM3020321	ATAC-seq on PBMCs from patient CLL5 on day 2 of ibrutinib treatment, CLL cells
GSM3020322	ATAC-seq on PBMCs from patient CLL5 on day 3 of ibrutinib treatment, CLL cells
GSM3020323	ATAC-seq on PBMCs from patient CLL5 on day 8 of ibrutinib treatment, CLL cells
GSM3020324	ATAC-seq on PBMCs from patient CLL5 on day 30 of ibrutinib treatment, CLL cells
GSM3020325	ATAC-seq on PBMCs from patient CLL5 on day 150 of ibrutinib treatment, CLL cells
GSM3020326	ATAC-seq on PBMCs from patient CLL5 on day 240 of ibrutinib treatment, CLL cells
GSM3020327	ATAC-seq on PBMCs from patient CLL5 on day 0 of ibrutinib treatment, Mono cells
GSM3020328	ATAC-seq on PBMCs from patient CLL5 on day 1 of ibrutinib treatment, Mono cells
GSM3020329	ATAC-seq on PBMCs from patient CLL5 on day 3 of ibrutinib treatment, Mono cells
GSM3020330	ATAC-seq on PBMCs from patient CLL5 on day 8 of ibrutinib treatment, Mono cells
GSM3020331	ATAC-seq on PBMCs from patient CLL5 on day 150 of ibrutinib treatment, Mono cells
GSM3020332	ATAC-seq on PBMCs from patient CLL5 on day 0 of ibrutinib treatment, NK cells
GSM3020333	ATAC-seq on PBMCs from patient CLL5 on day 1 of ibrutinib treatment, NK cells
GSM3020334	ATAC-seq on PBMCs from patient CLL5 on day 3 of ibrutinib treatment, NK cells
GSM3020335	ATAC-seq on PBMCs from patient CLL5 on day 8 of ibrutinib treatment, NK cells
GSM3020336	ATAC-seq on PBMCs from patient CLL5 on day 030 of ibrutinib treatment, NK cells
GSM3020337	ATAC-seq on PBMCs from patient CLL5 on day 30 of ibrutinib treatment, NK cells
GSM3020338	ATAC-seq on PBMCs from patient CLL6 on day 120 of ibrutinib treatment, Bcell cells
GSM3020339	ATAC-seq on PBMCs from patient CLL6 on day 280 of ibrutinib treatment, Bcell cells
GSM3020340	ATAC-seq on PBMCs from patient CLL6 on day 030 of ibrutinib treatment, CD4 cells
GSM3020341	ATAC-seq on PBMCs from patient CLL6 on day 120 of ibrutinib treatment, CD4 cells
GSM3020342	ATAC-seq on PBMCs from patient CLL6 on day 280 of ibrutinib treatment, CD4 cells
GSM3020343	ATAC-seq on PBMCs from patient CLL6 on day 0 of ibrutinib treatment, CD8 cells
GSM3020344	ATAC-seq on PBMCs from patient CLL6 on day 030 of ibrutinib treatment, CD8 cells
GSM3020345	ATAC-seq on PBMCs from patient CLL6 on day 120 of ibrutinib treatment, CD8 cells
GSM3020346	ATAC-seq on PBMCs from patient CLL6 on day 280 of ibrutinib treatment, CD8 cells
GSM3020347	ATAC-seq on PBMCs from patient CLL6 on day 0 of ibrutinib treatment, CLL cells
GSM3020348	ATAC-seq on PBMCs from patient CLL6 on day 030 of ibrutinib treatment, CLL cells
GSM3020349	ATAC-seq on PBMCs from patient CLL6 on day 120 of ibrutinib treatment, CLL cells
GSM3020350	ATAC-seq on PBMCs from patient CLL6 on day 280 of ibrutinib treatment, CLL cells
GSM3020351	ATAC-seq on PBMCs from patient CLL6 on day 0 of ibrutinib treatment, Mono cells
GSM3020352	ATAC-seq on PBMCs from patient CLL6 on day 030 of ibrutinib treatment, Mono cells
GSM3020353	ATAC-seq on PBMCs from patient CLL6 on day 120 of ibrutinib treatment, Mono cells
GSM3020354	ATAC-seq on PBMCs from patient CLL6 on day 280 of ibrutinib treatment, Mono cells
GSM3020355	ATAC-seq on PBMCs from patient CLL6 on day 030 of ibrutinib treatment, NK cells
GSM3020356	ATAC-seq on PBMCs from patient CLL6 on day 280 of ibrutinib treatment, NK cells
GSM3020357	ATAC-seq on PBMCs from patient CLL7 on day 0 of ibrutinib treatment, Bcell cells
GSM3020358	ATAC-seq on PBMCs from patient CLL7 on day 3 of ibrutinib treatment, Bcell cells
GSM3020359	ATAC-seq on PBMCs from patient CLL7 on day 150 of ibrutinib treatment, Bcell cells
GSM3020360	ATAC-seq on PBMCs from patient CLL7 on day 0 of ibrutinib treatment, CD4 cells
GSM3020361	ATAC-seq on PBMCs from patient CLL7 on day 1 of ibrutinib treatment, CD4 cells
GSM3020362	ATAC-seq on PBMCs from patient CLL7 on day 3 of ibrutinib treatment, CD4 cells
GSM3020363	ATAC-seq on PBMCs from patient CLL7 on day 8 of ibrutinib treatment, CD4 cells
GSM3020364	ATAC-seq on PBMCs from patient CLL7 on day 30 of ibrutinib treatment, CD4 cells
GSM3020365	ATAC-seq on PBMCs from patient CLL7 on day 150 of ibrutinib treatment, CD4 cells
GSM3020366	ATAC-seq on PBMCs from patient CLL7 on day 0 of ibrutinib treatment, CD8 cells
GSM3020367	ATAC-seq on PBMCs from patient CLL7 on day 1 of ibrutinib treatment, CD8 cells
GSM3020368	ATAC-seq on PBMCs from patient CLL7 on day 3 of ibrutinib treatment, CD8 cells
GSM3020369	ATAC-seq on PBMCs from patient CLL7 on day 8 of ibrutinib treatment, CD8 cells
GSM3020370	ATAC-seq on PBMCs from patient CLL7 on day 30 of ibrutinib treatment, CD8 cells
GSM3020371	ATAC-seq on PBMCs from patient CLL7 on day 150 of ibrutinib treatment, CD8 cells
GSM3020372	ATAC-seq on PBMCs from patient CLL7 on day 0 of ibrutinib treatment, CLL cells
GSM3020373	ATAC-seq on PBMCs from patient CLL7 on day 1 of ibrutinib treatment, CLL cells
GSM3020374	ATAC-seq on PBMCs from patient CLL7 on day 3 of ibrutinib treatment, CLL cells
GSM3020375	ATAC-seq on PBMCs from patient CLL7 on day 8 of ibrutinib treatment, CLL cells
GSM3020376	ATAC-seq on PBMCs from patient CLL7 on day 30 of ibrutinib treatment, CLL cells
GSM3020377	ATAC-seq on PBMCs from patient CLL7 on day 150 of ibrutinib treatment, CLL cells
GSM3020378	ATAC-seq on PBMCs from patient CLL7 on day 0 of ibrutinib treatment, NK cells
GSM3020379	ATAC-seq on PBMCs from patient CLL7 on day 30 of ibrutinib treatment, NK cells
GSM3020380	ATAC-seq on PBMCs from patient CLL7 on day 150 of ibrutinib treatment, NK cells
GSM3020381	ATAC-seq on PBMCs from patient CLL8 on day 0 of ibrutinib treatment, CD4 cells
GSM3020382	ATAC-seq on PBMCs from patient CLL8 on day 3 of ibrutinib treatment, CD4 cells
GSM3020383	ATAC-seq on PBMCs from patient CLL8 on day 0 of ibrutinib treatment, CD8 cells
GSM3020384	ATAC-seq on PBMCs from patient CLL8 on day 3 of ibrutinib treatment, CD8 cells
GSM3020385	ATAC-seq on PBMCs from patient CLL8 on day 030 of ibrutinib treatment, CD8 cells
GSM3020386	ATAC-seq on PBMCs from patient CLL8 on day 0 of ibrutinib treatment, CLL cells
GSM3020387	ATAC-seq on PBMCs from patient CLL8 on day 3 of ibrutinib treatment, CLL cells
GSM3020388	ATAC-seq on PBMCs from patient CLL8 on day 030 of ibrutinib treatment, CLL cells
GSM3020389	ATAC-seq on PBMCs from patient CLL8 on day 0 of ibrutinib treatment, Mono cells
GSM3020390	ATAC-seq on PBMCs from patient CLL8 on day 3 of ibrutinib treatment, Mono cells
GSM3020391	ATAC-seq on PBMCs from patient CLL8 on day 0 of ibrutinib treatment, NK cells
GSM3020392	ATAC-seq on PBMCs from patient CLL8 on day 3 of ibrutinib treatment, NK cells
GSM3020393	scRNA-seq on PBMCs from patient CLL1 after 0 days of ibrutinib treatment
GSM3020394	scRNA-seq on PBMCs from patient CLL1 after 120 days of ibrutinib treatment
GSM3020395	scRNA-seq on PBMCs from patient CLL5 after 0 days of ibrutinib treatment
GSM3020396	scRNA-seq on PBMCs from patient CLL5 after 150 days of ibrutinib treatment
GSM3020397	scRNA-seq on PBMCs from patient CLL5 after 30 days of ibrutinib treatment
GSM3020398	scRNA-seq on PBMCs from patient CLL6 after 0 days of ibrutinib treatment
GSM3020399	scRNA-seq on PBMCs from patient CLL6 after 120 days of ibrutinib treatment
GSM3020400	scRNA-seq on PBMCs from patient CLL6 after 280 days of ibrutinib treatment
GSM3020401	scRNA-seq on PBMCs from patient CLL6 after 30 days of ibrutinib treatment
GSM3020402	scRNA-seq on PBMCs from patient CLL8 after 0 days of ibrutinib treatment
GSM3020403	scRNA-seq on PBMCs from patient CLL8 after 120 days of ibrutinib treatment
GSM3020404	scRNA-seq on PBMCs from patient CLL8 after 30 days of ibrutinib treatment